<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="84465"><DrugName>CpG oligodeoxynucleotides (wound healing), NCI</DrugName><DrugSynonyms><Name><Value>CpG oligodeoxynucleotides (wound healing), NCI</Value></Name></DrugSynonyms><CompanyOriginator id="20519">National Cancer Institute</CompanyOriginator><CompaniesSecondary><Company id="20518">National Institutes of Health</Company><Company id="20519">National Cancer Institute</Company></CompaniesSecondary><CrossReferences><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="347">Wound healing</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="7292">Vulnerary agent</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="103">Oligonucleotide</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D3</Code><Name>WOUND HEALING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-24T04:30:15.000Z</LastModificationDate><ChangeDateLast>2018-04-26T00:00:00.000Z</ChangeDateLast><AddedDate>2013-04-12T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt; (NCI) was investigating CpG oligodeoxynucleotides (ODN)  for the potential treatment of wounds, including trauma or surgical wounds, and cancer. In March 2013, development was ongoing [&lt;ulink linkID="1395222" linkType="Reference"&gt;1395222&lt;/ulink&gt;]. In September 2015, this was still the case [&lt;ulink linkID="1697016" linkType="Reference"&gt;1697016&lt;/ulink&gt;].  In March 2013,  the NCI was seeking to outlicense the drug through &lt;ulink linkID="1042246" linkType="Company"&gt;National Institutes of Health Office of Technology Transfer&lt;/ulink&gt;  [&lt;ulink linkID="1395222" linkType="Reference"&gt;1395222&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By October 2009, data demonstrated that CpG oligodeoxynucleotide had stimulated epithelial cell division with induced wound healing [&lt;ulink linkID="1395222" linkType="Reference"&gt;1395222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2009, preclinical studies on topical ODNs had shown pappilomas developed in fewer animals [&lt;ulink linkID="1395222" linkType="Reference"&gt;1395222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-10-31T00:00:00.000Z</StatusDate><Source id="1395222" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-05-31T00:00:00.000Z</StatusDate><Source id="1395222" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-05-31T00:00:00.000Z</StatusDate><Source id="1395222" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-10-31T00:00:00.000Z</StatusDate><Source id="1395222" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>